Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany Decision Represents Early Step in Building the Company’s Foundation Internationally MENLO PARK, Calif.—January 29, 2016—Intersect

First Page		Document Content
Date: 2016-02-02 07:14:47 Medicine Intersect ENT Propel mometasone furoate implant Sinus implant Forward-looking statement Sinusitis Otorhinolaryngology Sinus Mometasone furoate		Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany Decision Represents Early Step in Building the Company’s Foundation Internationally MENLO PARK, Calif.—January 29, 2016—Intersect Add to Reading List Source URL: propelopens.com Download Document from Source Website File Size: 136,77 KB Share Document on Facebook

	IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION ASMANEX® Twisthaler® Mometasone Furoate Dry Powder Inhaler DocID: 1tYoJ - View Document
	PROPEL® mini (mometasone furoate implant, 370 µg) Instructions For Use CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE STERILE: STORAGE: DocID: 1suji - View Document
	PROPEL® (mometasone furoate implant, 370 µg) Instructions For Use CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE STERILE: STORAGE: DocID: 1qyzI - View Document
	Intersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients With Frontal Sinus Disease Results Demonstrate Clinical Benefits of PROPEL mini in Difficult-to-Treat Patient Population MENL DocID: 1pP5m - View Document
	Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis Company Also Announces Publication of Positive Six-Month Results from RESOLVE Clinica DocID: 1okP8 - View Document